Navigation Links
Cell Genesys Provides Final Median Survival Data From Second Phase,2 Trial of GVAX Immunotherapy for Prostate Cancer

being studied as a single agent and in combination with docetaxel chemotherapy in two Phase 3 clinical trials expected to enroll approximately 1,200 patients with metastatic HRPC. Cell Genesys received Special Protocol Assessments (SPA) from the Food and Drug Administration (FDA) for each of the Phase 3 studies and has also received Fast Track designation for the product. GVAX immunotherapy for prostate cancer is comprised of two prostate cancer cell lines that have been modified to secrete GM-CSF (granulocyte-macrophage colony stimulating factor), an immune stimulatory hormone, and irradiated for safety. GVAX cancer immunotherapy for prostate cancer is being developed as a non patient-specific, "off-the-shelf" pharmaceutical product.

Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently developing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at www.cellgenesys.com.

Statements made herein about the company, other than statements of historical fact, including statements about the company's progress, results and timing of clinical trials and preclinical programs and the nature of product pipelines are forward-looking statements and are subject to a number of uncertainties tha
'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
2. Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. XTL Provides Update on Phase I Clinical Trial of XTL-2125
5. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
6. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
7. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
8. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
9. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
10. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
11. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
Post Your Comments:
(Date:9/3/2015)... 2015 China,s startup ... Patch, a wearable medical device that can continuously monitor ... providing safety guidance for pregnant women. The device will ... device, which measures 4 centimeters in diameter, is as ... more than an Apple earphone cord. The small and ...
(Date:9/3/2015)... N.Y. , Sept. 3, 2015  VirtualScopics, ... of clinical trial imaging solutions, announced today, they ... support for a new philanthropic, epidemiology study partnering ... Africa .  VirtualScopics has teamed up with ... in Zambia.  The image results will be used ...
(Date:9/3/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4q3mv2/investigation ) has ... China Olmesartan Market, 2010-2019" report to their offering. ... developed by Sankyo Pharmaceuticals Co., Ltd and was patented ... approved by FDA to enter the American market in ... in the world after it succeeded in the US ...
Breaking Medicine Technology:Modoo to Debut at Kickstarter: First Device on the Market that Enables Continuous Monitoring of Fetal Heart Rate and Fetal Movement 2VirtualScopics, Inc. Collaborates with Large Pharmaceutical Company on a Philanthropic, Epidemiology Study in Africa 2VirtualScopics, Inc. Collaborates with Large Pharmaceutical Company on a Philanthropic, Epidemiology Study in Africa 3VirtualScopics, Inc. Collaborates with Large Pharmaceutical Company on a Philanthropic, Epidemiology Study in Africa 4China Olmesartan Investigation Market Report 2010-2019 2
... Ohio , May 24 Robbins & Myers, Inc. ... at the KeyBanc 2010 Capital Markets Industrial, Automotive & Transportation Conference ... held at the InterContinental Hotel in Boston .  Representing the ... Executive Officer, Christopher M. Hix , Vice President and CFO ...
... SILVER SPRING, Md. , May 24 Genzyme Corp. has signed a ... manufacturing facility and will turn over to the federal government $175 million ... the U.S. Food and Drug Administration announced today. , ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , , , ...
Cached Medicine Technology:Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits 2Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits 3
(Date:9/3/2015)... ... September 03, 2015 , ... DiabetesSisters Welcomes Carol ... announce the additional of Carol Wysham, MD, to their esteemed Board of Directors. ... Donna Rice, David Warren, Matt Stella, Tricia Cedotal, Andrea Thomas, Wanda Nicholson and ...
(Date:9/3/2015)... ... September 03, 2015 , ... ProScrub is a set of automated ... flicker, repeat, and custom speed effects without the use of keyframes. Utilize ProScrub's ... ProScrub tools are perfect complements to energetic video productions. ProScrub is a ...
(Date:9/3/2015)... ... 2015 , ... AvePoint, the established leader in enabling enterprise collaboration ... – AvePoint’s solution for facilitating two-way collaboration and external sharing without ever having ... This is the fifth consecutive year an AvePoint product has made the list. , ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... will be participating at the highly anticipated Mississippi Gulf Babypalooza on September 19, ... from all over, from Gulfport, Biloxi, and beyond. We will be discussing setting ...
(Date:9/3/2015)... ... ... at the types of people who have a hard time gaining weight , it ... appetite or those that have a fast metabolism. In order to help those people who ... tips for slowing down metabolism. , The first thing to do is to space out ...
Breaking Medicine News(10 mins):Health News:Carol H. Wysham, MD, Joins DiabetesSisters Board of Directors 2Health News:FCPX Effects Developer Releases ProScrub for Final Cut Pro X 2Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 2Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 3Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 4Health News:State Farm Agent EJ Roberts to Help Expecting Mothers at the Mississippi Gulf Babypalooza 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 3
... ... analyze senior care options including Assisted Living Facilities, Nursing Homes, Alzheimer,s Care Centers, Independent ... ... today the formal release of a new process-based tool for tabulating lists of senior ...
... , , WASHINGTON , Jan. 27 ... in Washington, D.C. , on Saturday, May 1, 2010 ... Forum. The focus of this year,s forum will be expansion and ... by the National Board of Certification for Medical Interpreters. , "While ...
... SAN DIEGO , Jan. 27 Neurocrine Biosciences, Inc. ... its fourth quarter and year-end 2009 financial results after the Nasdaq ... a  live conference call and webcast to discuss its financial results ... at 5:00 p.m. Eastern Time ( 2:00 p.m. ...
... United States has an inefficient and expensive health care system, ... care system detailed in a new study in the ... No. 2). According to the authors of ... Health Care System" from Ben-Gurion University of the Negev (BGU) ...
... for children with cerebral palsy are backed by sufficient ... review of scientific literature headed by a UT Southwestern ... of interdisciplinary experts nationwide. The findings prompted the ... guideline on effective treatments. Dr. Mauricio Delgado-Ayala, professor of ...
... A new study on the surface chemistry of silver-colored, ... mercury may be less toxic than previously thought. It ... Toxicology . In the study, Graham George and ... been used by dentists to repair teeth for well-over ...
Cached Medicine News:Health News:Assisted Senior Living Releases New Tool For Finding Assisted Living Facilities And Other Senior Care 2Health News:Assisted Senior Living Releases New Tool For Finding Assisted Living Facilities And Other Senior Care 3Health News:Leaders and Advocates Convene in Washington, D.C. for Fourth Annual National Medical Interpreter Certification - Open Forum 2Health News:Leaders and Advocates Convene in Washington, D.C. for Fourth Annual National Medical Interpreter Certification - Open Forum 3Health News:Leaders and Advocates Convene in Washington, D.C. for Fourth Annual National Medical Interpreter Certification - Open Forum 4Health News:Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2009 Financial Results 2Health News:Integrating private insurance with public health would improve US health care -- study 2Health News:Anti-spasticity medications need further research 2
... The Tangent Posterior Impacted Instrument Set ... Some of the advantages offered by the ... endplate preparation and the ability to reproduce ... heights to ensure proper vertebral body distraction. ...
Codman Hakim Programmable micro with Rickham Reservoir offers the ability to optimize the opening pressure of a shunt system before and after implantation. A shunted patient's condition will often ch...
... Osteopal V is a low viscosity bone ... in vertebroplasty. The bone cement is injected ... purposes. Osteopal V is used for the ... of zirconium dioxide is included in the ...
... to fuse multiple image sets in seconds, ... treatment planning and follow-up. ImageFusion aligns images ... features of different scan types. Radionics supports ... clinicians can capitalize on the unique strengths ...
Medicine Products: